Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
GLP‐1 is a peptide hormone from the intestinal mucosa. It is secreted in response to meal ingestion and normally functions in the so‐called ileal brake, that is, inhibition of upper gastrointestinal motility and secretion when nutrients are present in the distal small intestine. It also induces satiety and promotes tissue deposition of ingested glucose by stimulating insulin secretion. Thus, it is an essential incretin hormone. In addition, the hormone has been demonstrated to promote insulin biosynthesis and insulin gene expression and to have trophic effects on the beta cells. The trophic effects include proliferation of existing beta cells, maturation of new cells from duct progenitor cells and inhibition of apoptosis. Furthermore, glucagon secretion is inhibited. Because of these effects, the hormone effectively improves metabolism in patients with type 2 diabetes mellitus. Thus, continuous subcutaneous administration of the peptide for six weeks in patients with rather advanced disease greatly improved glucose profiles and lowered body weight, haemoglobin A 1 C, and free fatty acids (FFA). In addition, insulin sensitivity doubled and insulin responses to glucose were greatly improved. There were no side effects. Continuous administration is necessary because of rapid degradation by the enzyme dipeptidyl peptidase‐IV. Alternative approaches include the use of analogues that are resistant to the actions of the enzyme, as well as inhibitors of the enzyme. Both approaches have shown remarkable efficacy in both experimental and clinical studies. The GLP‐1‐based therapy of type 2 diabetes, therefore, represents a new and attractive alternative. Copyright © 2002 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“and reduce food intake in normal subjects [78,79].”
BackgroundSelf-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“[105], using an artificial pancreas to show that patients with type 2 diabetes need almost no insulin to maintain normal blood glucose if they were infused with GLP-1, and by Nathan et al, who found lower meal-induced glucose excursions in a few patients if given GLP-1 [106].”
MethodSelf-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Self-citation
Cited by
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
“However, its very short half-life, consequent to its rapid metabolism by the enzyme dipeptidyl peptidase-4 (DPP-4), limits its therapeutic potential [2].”
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Self-citationInsulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell‐Jones, D., & Khan, R. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 557
Nielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457
Incretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 444
Self-citationGlucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297
Self-citationTherapeutic Strategies Based on Glucagon-Like Peptide 1
Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296
Upregulation of insulin receptor substrate-2 in pancreatic β cells prevents diabetes
Hennige, A. M., Burks, D. J., Ozcan, U., Kulkarni, R. N., Ye, J., Park, S., Schubert, M., Fisher, T. L., Dow, M. A., Leshan, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18581 · Cited by 262
Preitner, F., Ibberson, M., Franklin, I., Binnert, C., Pende, M., Gjinovci, A., Hansotia, T., Drucker, D. J., Wollheim, C., Burcelin, R., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420518 · Cited by 256
Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217
Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass
Buteau, J., Spatz, M. L., & Accili, D. (2006) · Diabetes · doi:10.2337/db05-0825 · Cited by 178
de Heer, J., & Holst, J. J. (2007) · Diabetes · doi:10.2337/db06-0738 · Cited by 115
“It significantly ameliorates glucose homeostasis in diabetic patients by, among other effects, enhancing insulin and suppressing glucagon secretion (1,2).”
BackgroundSelf-citationBlase, E., Taylor, K., Gao, H., Wintle, M., & Fineman, M. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004274432 · Cited by 82
“These actions include glucose-dependent enhancement of insulin secretion,(5-11) suppression of inappropriately high glucagon secretion,(5,6,8,10,11) slowing of gastric emptying,(5,6,8,12) reduction of food intake and body weight,(8,10,12-15) and an increase in β-cell mass (animal studies) and function.(6,8,10,12,16) P…”
BackgroundExenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
“Some, but not all, studies also suggest that GLP-1 improves insulin sensitivity [26-28].”
BackgroundManagement of type 2 diabetes: the role of incretin mimetics
Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29
Metadata
- Authors
- Holst, J. J.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2002-11
- Volume
- 18
- Issue
- 6
- Pages
- 430-441
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2160757033
- Cited by
- 155
- References
- 34
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.